| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Wellgistics is an NABP Accredited Drug Distributor licensed in all 50 states. We are maniacal about compliance and never carry gray market products, 100% direct
Inimex Pharmaceuticals Inc. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NEW Health provides high quality health care services for all residents within the communities we serve. We offer a sliding fee discount for health services to those who qualify. We believe that all people deserve...
RW Troxell is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.